192 related articles for article (PubMed ID: 35927410)
1. An EQ-5D-5L Value Set for Belgium.
Bouckaert N; Cleemput I; Devriese S; Gerkens S
Pharmacoecon Open; 2022 Nov; 6(6):823-836. PubMed ID: 35927410
[TBL] [Abstract][Full Text] [Related]
2. A hybrid modelling approach for eliciting health state preferences: the Portuguese EQ-5D-5L value set.
Ferreira PL; Antunes P; Ferreira LN; Pereira LN; Ramos-Goñi JM
Qual Life Res; 2019 Dec; 28(12):3163-3175. PubMed ID: 31201730
[TBL] [Abstract][Full Text] [Related]
3. Valuation of EQ-5D-5L in the Kingdom of Saudi Arabia: A National Representative Study.
Al-Jedai A; Almudaiheem H; Al-Salamah T; Aldosari M; Almutairi AR; Almogbel Y; AlRuthia Y; Althemery AU; Alluhidan M; Roudijk B; Purba FD; Awad N; O'jeil R
Value Health; 2024 May; 27(5):552-561. PubMed ID: 38342365
[TBL] [Abstract][Full Text] [Related]
4. Dutch Tariff for the Five-Level Version of EQ-5D.
M Versteegh M; M Vermeulen K; M A A Evers S; de Wit GA; Prenger R; A Stolk E
Value Health; 2016 Jun; 19(4):343-52. PubMed ID: 27325326
[TBL] [Abstract][Full Text] [Related]
5. The Danish EQ-5D-5L Value Set: A Hybrid Model Using cTTO and DCE Data.
Jensen CE; Sørensen SS; Gudex C; Jensen MB; Pedersen KM; Ehlers LH
Appl Health Econ Health Policy; 2021 Jul; 19(4):579-591. PubMed ID: 33527304
[TBL] [Abstract][Full Text] [Related]
6. Development of an EQ-5D Value Set for India Using an Extended Design (DEVINE) Study: The Indian 5-Level Version EQ-5D Value Set.
Jyani G; Sharma A; Prinja S; Kar SS; Trivedi M; Patro BK; Goyal A; Purba FD; Finch AP; Rajsekar K; Raman S; Stolk E; Kaur M
Value Health; 2022 Jul; 25(7):1218-1226. PubMed ID: 35779943
[TBL] [Abstract][Full Text] [Related]
7. United States Valuation of EQ-5D-5L Health States Using an International Protocol.
Pickard AS; Law EH; Jiang R; Pullenayegum E; Shaw JW; Xie F; Oppe M; Boye KS; Chapman RH; Gong CL; Balch A; Busschbach JJV
Value Health; 2019 Aug; 22(8):931-941. PubMed ID: 31426935
[TBL] [Abstract][Full Text] [Related]
8. Utility Values for Health States in Ireland: A Value Set for the EQ-5D-5L.
Hobbins A; Barry L; Kelleher D; Shah K; Devlin N; Goni JMR; O'Neill C
Pharmacoeconomics; 2018 Nov; 36(11):1345-1353. PubMed ID: 30051267
[TBL] [Abstract][Full Text] [Related]
9. Comparison of Value Set Based on DCE and/or TTO Data: Scoring for EQ-5D-5L Health States in Japan.
Shiroiwa T; Ikeda S; Noto S; Igarashi A; Fukuda T; Saito S; Shimozuma K
Value Health; 2016; 19(5):648-54. PubMed ID: 27565282
[TBL] [Abstract][Full Text] [Related]
10. Valuation of EQ-5D-5L Health States in Poland: the First EQ-VT-Based Study in Central and Eastern Europe.
Golicki D; Jakubczyk M; Graczyk K; Niewada M
Pharmacoeconomics; 2019 Sep; 37(9):1165-1176. PubMed ID: 31161586
[TBL] [Abstract][Full Text] [Related]
11. The EQ-5D-5L Valuation Study in Egypt.
Al Shabasy S; Abbassi M; Finch A; Roudijk B; Baines D; Farid S
Pharmacoeconomics; 2022 Apr; 40(4):433-447. PubMed ID: 34786590
[TBL] [Abstract][Full Text] [Related]
12. An EQ-5D-5L value set for Italy using videoconferencing interviews and feasibility of a new mode of administration.
Finch AP; Meregaglia M; Ciani O; Roudijk B; Jommi C
Soc Sci Med; 2022 Jan; 292():114519. PubMed ID: 34736804
[TBL] [Abstract][Full Text] [Related]
13. The EQ-5D-5L valuation study in Korea.
Kim SH; Ahn J; Ock M; Shin S; Park J; Luo N; Jo MW
Qual Life Res; 2016 Jul; 25(7):1845-52. PubMed ID: 26961008
[TBL] [Abstract][Full Text] [Related]
14. Valuing Health State: An EQ-5D-5L Value Set for Ethiopians.
Welie AG; Gebretekle GB; Stolk E; Mukuria C; Krahn MD; Enquoselassie F; Fenta TG
Value Health Reg Issues; 2020 Sep; 22():7-14. PubMed ID: 31683254
[TBL] [Abstract][Full Text] [Related]
15. Valuation of the EQ-5D-3L in Russia.
Omelyanovskiy V; Musina N; Ratushnyak S; Bezdenezhnykh T; Fediaeva V; Roudijk B; Purba FD
Qual Life Res; 2021 Jul; 30(7):1997-2007. PubMed ID: 33713323
[TBL] [Abstract][Full Text] [Related]
16. Peruvian Valuation of the EQ-5D-5L: A Direct Comparison of Time Trade-Off and Discrete Choice Experiments.
Augustovski F; Belizán M; Gibbons L; Reyes N; Stolk E; Craig BM; Tejada RA
Value Health; 2020 Jul; 23(7):880-888. PubMed ID: 32762989
[TBL] [Abstract][Full Text] [Related]
17. Valuing health-related quality of life using a hybrid approach: Tunisian value set for the EQ-5D-3L.
Chemli J; Drira C; Felfel H; Roudijk B; Al Sayah F; Kouki M; Kooli A; Razgallah Khrouf M
Qual Life Res; 2021 May; 30(5):1445-1455. PubMed ID: 33447958
[TBL] [Abstract][Full Text] [Related]
18. The Indonesian EQ-5D-5L Value Set.
Purba FD; Hunfeld JAM; Iskandarsyah A; Fitriana TS; Sadarjoen SS; Ramos-Goñi JM; Passchier J; Busschbach JJV
Pharmacoeconomics; 2017 Nov; 35(11):1153-1165. PubMed ID: 28695543
[TBL] [Abstract][Full Text] [Related]
19. The EQ-5D-5L Valuation Study in Egypt.
Al Shabasy SA; Abbassi MM; Finch AP; Baines D; Farid SF
Pharmacoeconomics; 2021 May; 39(5):549-561. PubMed ID: 33709283
[TBL] [Abstract][Full Text] [Related]
20. The EQ-5D-5L Valuation study in Thailand.
Pattanaphesaj J; Thavorncharoensap M; Ramos-Goñi JM; Tongsiri S; Ingsrisawang L; Teerawattananon Y
Expert Rev Pharmacoecon Outcomes Res; 2018 Oct; 18(5):551-558. PubMed ID: 29958008
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]